FDA Approval Activities for this Drug…

Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275/S10 & S12 8/25/03 8/28/03 8/28/03 Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275/S6 8/26/02 8/30/02 8/26/02 Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275 3/16/01 4/19/01 8/20/01 Lumigan Indications: for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive [failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. Lumigan (bimatoprost ophthalmic solution), Allergan,

For the latest approval information, please see the main page.